Phase 2 N=101 LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
Atherosclerosis · Vascular Disease · Arteriosclerosis
Primary: Angiographic Late Lumen Loss — 0.46; 1.09 mm — p=0.016
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=13 Effect of Octreotide on the Colonic Motility in Pediatric Patients
Colonic Motility Index · Constipation
Primary: Compared Colonic Motility Index From Fasting to Post Octreotide Infusion — 6.03; 6.89; 7.73; 5.32 mm Hg — p=0.087
Phase 2 N=13 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
N/A N=102 Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes
Coronary Heart Disease · Stroke · Renal Failure
Primary: Cardiovascular Mortality — 7; 11 participants — p=0.30
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
Phase 3 N=401 Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
Asthma
Primary: FEV1 Peak(0-3h) Change From Baseline — 0.252; 0.287; 0.391 Litres — p=0.2724
N/A N=2,239 Universal Screening for Tuberculosis and Anemia With the CHICA System
Tuberculosis · Iron Deficiency Anemia
Primary: Percentage of Patients Screened Positive for One of the Disorders — 17.5; 3.1; 1.8; 0.8 percentage of participants
Phase 4 N=380 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
Idiopathic Parkinson's Disease
Primary: Change From Baseline to the End of Maintenance Period in the Score of the Hamilton Depression Scale (HAM-D) — -4.79; -3.68 units on a scale — p==0.1286
Phase 1 N=10 A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
Chronic Interstitial Cystitis
Primary: Percentage of Participants by Change From Baseline in Appearance of Hunner's Lesions at Day 14 — 0.0; 85.7; 14.3; 0.0 percentage of participants
Phase 2 N=37 Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study
Hypertension
Primary: Mean Nighttime Systolic Blood Pressure (SBP) — 126.6; 125.3 mmHg — p=0.075
N/A N=105 Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea
Non-small Cell Lung Cancer (NSCLC)
Primary: Occurrence of Prolonged Air Leaks — 0.0; 5.8; 37.5 percentage of participants
N/A N=80 Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee
Knee Injuries
Primary: Degree of Filling of the Lesion by Repair Tissue at 12 Months Through MRI. — 92.81; 85.22 Percentage of lesion fill — p=0.011
Phase 3 N=139 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Non-hodgkin Lymphoma · Hodgkin Lymphoma
Primary: To Compare 2-year Overall Survival of Patients With Lymphoma Undergoing RIC SCT Between Those Receiving Tacrolimus/Sirolimus/Methotrexate and Those Receiving…
N/A N=32 Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Hypophosphatasia (HPP)
Primary: Radiographic Global Impression of Change - RGI-C — 0.33 units on a scale — p=0.0755
Phase 2 N=40 Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
Hypertension
Primary: Mean Nighttime Systolic Blood Pressure (SBP) — 126.6; 127.9 mmHg — p=0.0269